Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Stock Information for Personalis Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Personalis Inc.

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
Personalis Reports Third Quarter 2025 Financial Results
Personalis to Announce Third Quarter 2025 Financial Results
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.